Is BaF3 bioassay useful to identify patients with bioinactive growth hormone?

Sara Pagani, Eduardo A. Chaler, Cristina Meazza, Mercedes Maceiras, Maria Eugenia Gonzalez, Marco A. Rivarola, Francesca Cantoni, Paola Travaglino, Lucia Delia Croce, Kamilia Laarej, Mauro Bozzola, Alicia Belgorosky

Research output: Contribution to journalArticle

2 Citations (Scopus)

Abstract

We analyzed the ability of the BaF3 cell line bioassay to select patients with biologically inactive GH. We first evaluated the biological response of the Ba/F3-hGHR cells to rhGH additional doses from 10 to 5000 pg/ml. The concentration points corresponding to the linear part of the curve were selected. We then analyzed a group of sera, diluted like the standard, including the entire range of GH concentrations that can be analyzed by bioassay. The serum/standard area below the curve ratio was calculated. Serum GH immunoactivity determined by IMMULITE/ GH bioactivity ratios was calculated. Our experimental data showed that GH-bioactivity/GH-immunoactivity ratios below 0.303 are indicative of a bioinactive GH molecule. This bioassay would recognize only extreme cases of GH bioinactivity, and it would not be a useful tool in the search for patients with altered forms of GH.

Original languageEnglish
Pages (from-to)783-788
Number of pages6
JournalJournal of Pediatric Endocrinology and Metabolism
Volume23
Issue number8
DOIs
Publication statusPublished - Aug 2010

Fingerprint

Biological Assay
Growth Hormone
Serum
Cell Line

Keywords

  • Bioassay
  • Cell line
  • Gene mutation
  • GH biological activity
  • Growth hormone

ASJC Scopus subject areas

  • Endocrinology
  • Endocrinology, Diabetes and Metabolism
  • Pediatrics, Perinatology, and Child Health

Cite this

Pagani, S., Chaler, E. A., Meazza, C., Maceiras, M., Gonzalez, M. E., Rivarola, M. A., ... Belgorosky, A. (2010). Is BaF3 bioassay useful to identify patients with bioinactive growth hormone? Journal of Pediatric Endocrinology and Metabolism, 23(8), 783-788. https://doi.org/10.1515/jpem.2010.128

Is BaF3 bioassay useful to identify patients with bioinactive growth hormone? / Pagani, Sara; Chaler, Eduardo A.; Meazza, Cristina; Maceiras, Mercedes; Gonzalez, Maria Eugenia; Rivarola, Marco A.; Cantoni, Francesca; Travaglino, Paola; Croce, Lucia Delia; Laarej, Kamilia; Bozzola, Mauro; Belgorosky, Alicia.

In: Journal of Pediatric Endocrinology and Metabolism, Vol. 23, No. 8, 08.2010, p. 783-788.

Research output: Contribution to journalArticle

Pagani, S, Chaler, EA, Meazza, C, Maceiras, M, Gonzalez, ME, Rivarola, MA, Cantoni, F, Travaglino, P, Croce, LD, Laarej, K, Bozzola, M & Belgorosky, A 2010, 'Is BaF3 bioassay useful to identify patients with bioinactive growth hormone?', Journal of Pediatric Endocrinology and Metabolism, vol. 23, no. 8, pp. 783-788. https://doi.org/10.1515/jpem.2010.128
Pagani, Sara ; Chaler, Eduardo A. ; Meazza, Cristina ; Maceiras, Mercedes ; Gonzalez, Maria Eugenia ; Rivarola, Marco A. ; Cantoni, Francesca ; Travaglino, Paola ; Croce, Lucia Delia ; Laarej, Kamilia ; Bozzola, Mauro ; Belgorosky, Alicia. / Is BaF3 bioassay useful to identify patients with bioinactive growth hormone?. In: Journal of Pediatric Endocrinology and Metabolism. 2010 ; Vol. 23, No. 8. pp. 783-788.
@article{df2610aee8d6462fa4435600bf9000e5,
title = "Is BaF3 bioassay useful to identify patients with bioinactive growth hormone?",
abstract = "We analyzed the ability of the BaF3 cell line bioassay to select patients with biologically inactive GH. We first evaluated the biological response of the Ba/F3-hGHR cells to rhGH additional doses from 10 to 5000 pg/ml. The concentration points corresponding to the linear part of the curve were selected. We then analyzed a group of sera, diluted like the standard, including the entire range of GH concentrations that can be analyzed by bioassay. The serum/standard area below the curve ratio was calculated. Serum GH immunoactivity determined by IMMULITE/ GH bioactivity ratios was calculated. Our experimental data showed that GH-bioactivity/GH-immunoactivity ratios below 0.303 are indicative of a bioinactive GH molecule. This bioassay would recognize only extreme cases of GH bioinactivity, and it would not be a useful tool in the search for patients with altered forms of GH.",
keywords = "Bioassay, Cell line, Gene mutation, GH biological activity, Growth hormone",
author = "Sara Pagani and Chaler, {Eduardo A.} and Cristina Meazza and Mercedes Maceiras and Gonzalez, {Maria Eugenia} and Rivarola, {Marco A.} and Francesca Cantoni and Paola Travaglino and Croce, {Lucia Delia} and Kamilia Laarej and Mauro Bozzola and Alicia Belgorosky",
year = "2010",
month = "8",
doi = "10.1515/jpem.2010.128",
language = "English",
volume = "23",
pages = "783--788",
journal = "Journal of Pediatric Endocrinology and Metabolism",
issn = "0334-018X",
publisher = "Walter de Gruyter GmbH & Co. KG",
number = "8",

}

TY - JOUR

T1 - Is BaF3 bioassay useful to identify patients with bioinactive growth hormone?

AU - Pagani, Sara

AU - Chaler, Eduardo A.

AU - Meazza, Cristina

AU - Maceiras, Mercedes

AU - Gonzalez, Maria Eugenia

AU - Rivarola, Marco A.

AU - Cantoni, Francesca

AU - Travaglino, Paola

AU - Croce, Lucia Delia

AU - Laarej, Kamilia

AU - Bozzola, Mauro

AU - Belgorosky, Alicia

PY - 2010/8

Y1 - 2010/8

N2 - We analyzed the ability of the BaF3 cell line bioassay to select patients with biologically inactive GH. We first evaluated the biological response of the Ba/F3-hGHR cells to rhGH additional doses from 10 to 5000 pg/ml. The concentration points corresponding to the linear part of the curve were selected. We then analyzed a group of sera, diluted like the standard, including the entire range of GH concentrations that can be analyzed by bioassay. The serum/standard area below the curve ratio was calculated. Serum GH immunoactivity determined by IMMULITE/ GH bioactivity ratios was calculated. Our experimental data showed that GH-bioactivity/GH-immunoactivity ratios below 0.303 are indicative of a bioinactive GH molecule. This bioassay would recognize only extreme cases of GH bioinactivity, and it would not be a useful tool in the search for patients with altered forms of GH.

AB - We analyzed the ability of the BaF3 cell line bioassay to select patients with biologically inactive GH. We first evaluated the biological response of the Ba/F3-hGHR cells to rhGH additional doses from 10 to 5000 pg/ml. The concentration points corresponding to the linear part of the curve were selected. We then analyzed a group of sera, diluted like the standard, including the entire range of GH concentrations that can be analyzed by bioassay. The serum/standard area below the curve ratio was calculated. Serum GH immunoactivity determined by IMMULITE/ GH bioactivity ratios was calculated. Our experimental data showed that GH-bioactivity/GH-immunoactivity ratios below 0.303 are indicative of a bioinactive GH molecule. This bioassay would recognize only extreme cases of GH bioinactivity, and it would not be a useful tool in the search for patients with altered forms of GH.

KW - Bioassay

KW - Cell line

KW - Gene mutation

KW - GH biological activity

KW - Growth hormone

UR - http://www.scopus.com/inward/record.url?scp=77958588947&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=77958588947&partnerID=8YFLogxK

U2 - 10.1515/jpem.2010.128

DO - 10.1515/jpem.2010.128

M3 - Article

VL - 23

SP - 783

EP - 788

JO - Journal of Pediatric Endocrinology and Metabolism

JF - Journal of Pediatric Endocrinology and Metabolism

SN - 0334-018X

IS - 8

ER -